Characterization of apolipoprotein plasma triacylglycerol regulation

被引:38
作者
Wong, Kasuen
Ryan, Robert O.
机构
[1] Childrens Hosp, Oakland Res Inst, Ctr Prevent Obes Diabet & Cardiovasc Dis, Oakland, CA 94609 USA
[2] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA
关键词
apolipoprotein A-V; lipoprotein lipase; metabolism; structure; -function; triacylglycerol;
D O I
10.1097/MOL.0b013e328133856c
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purpose of review Cardiovascular disease is the leading cause of death in the USA, and hypertriglyceridemia represents an independent risk factor contributing to its premature onset. Apolipoprotein (apo)A-V has been shown to be a potent regulator of plasma triacylglycerol. We highlight structural aspects of apoA-V and discuss recent findings that provide mechanistic insight into its function as a regulator of plasma triacylglycerol metabolism. Recent findings Recent findings indicate that apoA-V is comprised of two independently folded domains. Fluorescence spectroscopy and truncation analysis revealed that the carboxyl-terminal region functions in apoA-V lipid binding, consistent with its known association with plasma lipoproteins. An indirect triacylglyceroi-modulating effect of apoA-V has been attributed to heparan sulfate proteoglycan binding, as confirmed by structural studies. Furthermore, apoA-V has been shown to interact with cell surface receptors, potentially facilitating lipoprotein particle endocytosis. Summary Several features of apoA-V, including extremely low plasma concentration, lack of correlation with plasma cholesterol levels despite its association with HDL, and insolubility at neutral pH in the absence of lipid, are unlike those of other exchangeable apolipoproteins. Current and future studies of apoA-V will help to shed light on the molecular basis whereby this protein functions to modulate plasma lipid homeostasis.
引用
收藏
页码:319 / 324
页数:6
相关论文
共 40 条
[1]   RETRACTED: Crystal structure of human apolipoprotein A-I: Insights into its protective effect against cardiovascular diseases (Retracted article. See vol. 115, pg. E6966, 2018) [J].
Ajees, AA ;
Anantharamaiah, GM ;
Mishra, VK ;
Hussain, MM ;
Murthy, HMK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (07) :2126-2131
[2]   Definitive N-terminal protein sequence and further characterization of the novel apolipoprotein A5 in human serum [J].
Alborn, WE ;
Johnson, MG ;
Prince, MJ ;
Konrad, RJ .
CLINICAL CHEMISTRY, 2006, 52 (03) :514-517
[3]   Altered apolipoprotein A-V expression during the acute phase response is independent of plasma triglyceride levels in mice and humans [J].
Becker, S ;
Schomburg, L ;
Renko, K ;
Tölle, M ;
van der Giet, M ;
Tietge, UJF .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 339 (03) :833-839
[4]   Structure-function studies of human apolipoprotein A-V: A regulator of plasma lipid homeostasis [J].
Beckstead, JA ;
Oda, MN ;
Martin, DDO ;
Forte, TM ;
Bielicki, JK ;
Berger, T ;
Luty, R ;
Kay, CM ;
Ryan, RO .
BIOCHEMISTRY, 2003, 42 (31) :9416-9423
[5]  
BECKSTEAD JA, 2007, J BIOL CHEM
[6]   APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency [J].
Calandra, S ;
Oliva, CP ;
Tarugi, P ;
Bertolini, S .
CURRENT OPINION IN LIPIDOLOGY, 2006, 17 (02) :122-127
[7]   Plasma apolipoprotein A5 and triglycerides in type 2 diabetes [J].
Dallinga-Thie, G. M. ;
Van Tol, A. ;
Hattori, H. ;
Zee, L. C. Van Vark-Van der ;
Jansen, H. ;
Sijbrands, E. J. G. .
DIABETOLOGIA, 2006, 49 (07) :1505-1511
[8]   Apoliprotein structural organisation in high density lipoproteins: belts, bundles, hinges and hairpins [J].
Davidson, WS ;
Silva, RAGD .
CURRENT OPINION IN LIPIDOLOGY, 2005, 16 (03) :295-300
[9]   Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5 [J].
Fruchart-Najib, J ;
Baugé, E ;
Niculescu, LS ;
Pham, T ;
Thomas, B ;
Rommens, C ;
Majd, Z ;
Brewer, B ;
Pennacchio, LA ;
Fruchart, JC .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 319 (02) :397-404
[10]   Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants [J].
Grosskopf, I ;
Baroukh, N ;
Lee, SJ ;
Kamari, Y ;
Harats, D ;
Rubin, EM ;
Pennacchio, LA ;
Cooper, AD .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (12) :2573-2579